中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2015年
1期
58-61
,共4页
帅智闯%史常勤%刘传令%丁东
帥智闖%史常勤%劉傳令%丁東
수지틈%사상근%류전령%정동
肺疾病,慢性阻塞性%噻托溴铵%半剂量%肺功能%6 min步行试验
肺疾病,慢性阻塞性%噻託溴銨%半劑量%肺功能%6 min步行試驗
폐질병,만성조새성%새탁추안%반제량%폐공능%6 min보행시험
Pulmonary disease,chronic obstructive%Tiotropium%Semi dose%Pulmonary function%6-minute walk test
目的 评价每日1次吸入9μg噻托溴铵对中重度慢性阻塞性肺疾病(COPD)患者的疗效.方法 采用随机数字表法将171例中重度COPD患者分成两组,半量组86例采用每日1次吸入9μg噻托溴铵粉吸入剂,对照组85例则采用推荐剂量每日1次吸入18 μg噻托溴铵粉吸入剂,应用6个月.在用药前、用药后3个月、用药后6个月分别测定患者肺功能和6 min步行试验.结果 两组患者无论肺功能指标还是6 min步行试验距离在两个研究时间段的增加值均高于用药前.用药后6个月两组患者与用药前比较,对照组第1秒用力呼气容积(FEV1)增加(0.21±0.12)L,上升率(19.31±10.61)％;半量组FEV1增加(0.22±0.13)L,上升率(19.25±11.52)％.对照组用力肺活量(FVC)增加(0.22±0.10)L,上升率(11.63±5.31)％,半量组FVC增加(0.23 ±0.15)L,上升率为(11.62±6.45)％.6 min步行试验距离两组患者较用药前均有明显改善,对照组患者用药后6个月较用药前增加(29.24±11.92)m,上升率(18.30±3.77)％.半量组患者用药后6个月较用药前增加(29.14±11.89)m,上升率(18.20±3.85)％.在两个时间段内患者急性加重和再入院情况组间比较差异无统计学意义(P＞0.05),半量组6个月与3个月比较虽然急性加重和再入院例数均有所减少但差异无统计学意义(P＞0.05).结论 噻托溴铵9μg每日1次吸入疗法对于国人长期(6个月后)疗效与推荐18μg每日1次吸入疗法相当.
目的 評價每日1次吸入9μg噻託溴銨對中重度慢性阻塞性肺疾病(COPD)患者的療效.方法 採用隨機數字錶法將171例中重度COPD患者分成兩組,半量組86例採用每日1次吸入9μg噻託溴銨粉吸入劑,對照組85例則採用推薦劑量每日1次吸入18 μg噻託溴銨粉吸入劑,應用6箇月.在用藥前、用藥後3箇月、用藥後6箇月分彆測定患者肺功能和6 min步行試驗.結果 兩組患者無論肺功能指標還是6 min步行試驗距離在兩箇研究時間段的增加值均高于用藥前.用藥後6箇月兩組患者與用藥前比較,對照組第1秒用力呼氣容積(FEV1)增加(0.21±0.12)L,上升率(19.31±10.61)％;半量組FEV1增加(0.22±0.13)L,上升率(19.25±11.52)％.對照組用力肺活量(FVC)增加(0.22±0.10)L,上升率(11.63±5.31)％,半量組FVC增加(0.23 ±0.15)L,上升率為(11.62±6.45)％.6 min步行試驗距離兩組患者較用藥前均有明顯改善,對照組患者用藥後6箇月較用藥前增加(29.24±11.92)m,上升率(18.30±3.77)％.半量組患者用藥後6箇月較用藥前增加(29.14±11.89)m,上升率(18.20±3.85)％.在兩箇時間段內患者急性加重和再入院情況組間比較差異無統計學意義(P＞0.05),半量組6箇月與3箇月比較雖然急性加重和再入院例數均有所減少但差異無統計學意義(P＞0.05).結論 噻託溴銨9μg每日1次吸入療法對于國人長期(6箇月後)療效與推薦18μg每日1次吸入療法相噹.
목적 평개매일1차흡입9μg새탁추안대중중도만성조새성폐질병(COPD)환자적료효.방법 채용수궤수자표법장171례중중도COPD환자분성량조,반량조86례채용매일1차흡입9μg새탁추안분흡입제,대조조85례칙채용추천제량매일1차흡입18 μg새탁추안분흡입제,응용6개월.재용약전、용약후3개월、용약후6개월분별측정환자폐공능화6 min보행시험.결과 량조환자무론폐공능지표환시6 min보행시험거리재량개연구시간단적증가치균고우용약전.용약후6개월량조환자여용약전비교,대조조제1초용력호기용적(FEV1)증가(0.21±0.12)L,상승솔(19.31±10.61)％;반량조FEV1증가(0.22±0.13)L,상승솔(19.25±11.52)％.대조조용력폐활량(FVC)증가(0.22±0.10)L,상승솔(11.63±5.31)％,반량조FVC증가(0.23 ±0.15)L,상승솔위(11.62±6.45)％.6 min보행시험거리량조환자교용약전균유명현개선,대조조환자용약후6개월교용약전증가(29.24±11.92)m,상승솔(18.30±3.77)％.반량조환자용약후6개월교용약전증가(29.14±11.89)m,상승솔(18.20±3.85)％.재량개시간단내환자급성가중화재입원정황조간비교차이무통계학의의(P＞0.05),반량조6개월여3개월비교수연급성가중화재입원례수균유소감소단차이무통계학의의(P＞0.05).결론 새탁추안9μg매일1차흡입요법대우국인장기(6개월후)료효여추천18μg매일1차흡입요법상당.
Objective To evaluate the efficacy of 9 μ g tiotropium inhalation once daily in patients with moderate to severe chronic obstructive pulmonary disease(COPD).Methods One hundred seventy-one patients with moderate to severe COPD were divided into two groups by random digits table methods:86 patients in test group who used 9 μ g tiotropium powder inhaler once daily,and 85 patients in control group who used the recommended dose 18 μ g once daily,both for 6 months.Patients' pulmonary function and 6-minute walk test were measured before treatment,3 months after treatment and 6 months after treatment.Results Two groups were compared 6 months after treatment.The level of forced expiratory volume in first second(FEV1) in the control group increased an average of (0.21 ± 0.12) L,and the rising rate was (19.31 ± 10.61)％.The level of FEV1 in test group increased (0.22 ±0.13) L,and the rising rate was (19.25 ± 11.52)％.The level of forced vital capacity (FVC) in control group increased an average of (0.22 ±0.10) L,and the rising rate was (11.63 ±5.31)％.The level of FVC in test group increased (0.23 ± 0.15) L,and the rising rate was (11.62 ± 6.45)％.The distance of 6-minute walk test in control group increased an average of (29.24 ± 11.92) m after treatment for 6 months,and the rising rate was (18.30 ± 3.77)％.The distance of 6-minute walk test in test group increased an average of (29.14 ± 11.89) m,and the rising rate was (18.20 ± 3.85)％.The number of acute exacerbations and rehospitalizations in two groups at these period had no significant difference (P ＞ 0.05).As for the test group,though the number of acute exacerbations and rehospitalizations decreased,there were no significant differences (P ＞ 0.05).Conclusions The effect of inhalation therapy of 9 μ g tiotropium once daily is more or less the same with that of 18 μ g once daily.
